12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multidrug resistance (MDR), a phenomenon that often occurs with drug treatment and is characterized by relapse or attenuation of drug efficacy, is almost unavoidable in colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy. MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate gene expression. Our previous study has identified miR-139-5p as a potential tumor suppressor in CRC, but its role in chemoresistance of CRC has not been elucidated. In this study, we demonstrated that miR-139-5p was down-regulated either in CRC tumors receiving chemotherapy or in 5-FU-resistant CRC cell lines (HCT-8/5-FU and HCT-116/5-FU). Ectopic expression of miR-139-5p sensitized CRC cells to 5-FU by increasing 5-FU-induced apoptosis. In addition, miR-139-5p inhibited the expression of the miR-139-5p target gene NOTCH-1 and its downstream molecules MRP-1 and BCL-2, two key MDR-associated genes. Furthermore, silencing NOTCH-1 expression promoted the chemotherapeutic effects of 5-FU, and up-regulation of NOTCH-1 abrogated miR-139-5p-mediated sensitization to 5-FU in LoVo and HCT-116 cells. Taken together, our data indicate a new role of miR-139-5p/NOTCH-1 pathway in the drug resistance of CRC cells to 5-FU, which may be a promising therapeutic target for the anti-MDR treatment of CRC.

          Related collections

          Author and article information

          Journal
          Pathol. Res. Pract.
          Pathology, research and practice
          Elsevier BV
          1618-0631
          0344-0338
          Jul 2016
          : 212
          : 7
          Affiliations
          [1 ] Wuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Department of Cardiothoracic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China.
          [2 ] Wuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China.
          [3 ] Wuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Department of Cardiothoracic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China. Electronic address: wxsytsg@126.com.
          [4 ] Wuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China. Electronic address: hzhwxsy@126.com.
          Article
          S0344-0338(16)30079-6
          10.1016/j.prp.2016.04.011
          27173050
          1fecf3ac-e710-45fd-8ce4-035d67257549
          History

          Chemoresistance,Colorectal cancer,NOTCH-1,miR-139-5p
          Chemoresistance, Colorectal cancer, NOTCH-1, miR-139-5p

          Comments

          Comment on this article